Loading organizations...
§ Private Profile · Suzhou, Jiangsu, China
Develops tumor immunology drugs and therapeutic antibodies for oncology. Licenses clinical-stage products to pharmaceutical companies.
Furong Biotech, formally known as Suzhou Forlong Biotechnology Company Limited, is a Suzhou, China-based biotechnology enterprise developing innovative tumor immunology drugs with a specific focus on therapeutic antibodies and novel antibody structures. The organization advances its proprietary oncology product pipeline through various clinical trial stages across both the Chinese and United States regulatory markets. Several therapeutic drugs originally developed by the internal scientific team have successfully reached clinical stages and been licensed to major global pharmaceutical corporations, including Pfizer and Merck. The enterprise is led by the founding team of Chief Executive Officer Tianlei Ying, Chairman Ji En, and Chief Technology Officer Yanling Wu. The company is financially backed by institutional venture capital investors such as Co-Win Ventures, represented by Managing Partner Xin Huang, supporting its ongoing research and clinical development initiatives within the broader oncology sector.
Furong Biotech has raised $14.7M across 1 funding round.
Furong Biotech has raised $14.7M in total across 1 funding round.
Furong Biotech has raised $14.7M in total across 1 funding round.
Furong Biotech's investors include Co-win Ventures, Fangfu Venture Capital, Haoyue Capital, Siyang Yu.
Furong Biotech has raised $14.7M across 1 funding round. Most recently, it raised $14.7M Series A in February 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 6, 2023 | $14.7M Series A | — | Co WIN Ventures, Fangfu Venture Capital, Haoyue Capital, Siyang YU | Announced |